Eli Lilly - GLP-1 RAs lawsuits & claims

Headquartered in Indianapolis, Indiana, Eli Lilly and Co. was established in 1876. Since its founding, this pharmaceutical giant has expanded tremendously and is now offering its products to 105 countries.

Eli Lilly is focused on manufacturing medications that treat metabolic disorders, particularly diabetes and obesity. Alongside Novo Nordisk, it’s one of the leaders in the research and development of GLP-1 receptor agonists (GLP-1 RAs). There are three GLP-1 RA drugs manufactured by Eli Lilly:

• Trulicity - This medication received FDA approval in 2014. Its active ingredient is dulaglutide, and it’s an injectable form of GLP-1 RA for the treatment of type 2 diabetes.
• Mounjaro - It is a dual GIP and GLP-1 RA that has tirzepatide as its active ingredient. Mounjaro is primarily manufactured for type 2 diabetes.
• Zepbound - Like Mounjaro, Zepbound has also tirzepatide as the active ingredient. The difference is that Zepbound is approved for weight management instead of diabetes treatment.

Other than these three, two other GLP-1 RA medications are being developed by Eli Lilly: Orforglipron and Retatrutide. Both are still experimental drugs.

Eli Lilly's medications linked to severe gastrointestinal conditions and vision loss

GLP-1 RAs are effective at treating type 2 diabetes and managing weight because, when administered, they mimic a hormone in the body that regulates blood sugar and controls appetite. However, these also result in serious health hazards that can affect one's livelihood and quality of life.

GLP-1 RAs are shown to cause gastroparesis, which is the partial or complete paralysis of the stomach. When this happens, food remains longer in the stomach, which results in nausea, vomiting, and abdominal pain. There’s no known cure for it yet. Another health hazard to watch out for is vision loss. It comes in the form of a painless and sudden vision loss called non-arteritic anterior ischemic optic neuropathy (NAION). Eli Lilly's weight loss injections can also cause bowel obstruction. 

Eli Lilly is involved in a multidistrict litigation

Eli Lilly and Novo Nordisk are currently facing over 1,300 pending lawsuits. The US Judicial Panel on Multidistrict Litigation (JPML) has consolidated these cases into MDL 3094: IN RE: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAs) PRODUCTS LIABILITY LITIGATION.

Atraxia Law provides legal assistance for weight loss injection claims

The eligibility of a GLP-1 RA case will depend on the following:

• Victim must not have pre-existing gastroparesis, vision loss, or bowel obstruction before taking GLP-1 RA medications
• Victim must have undergone at least one round of Trulicity, Mounjaro, or Zepbound
• Victim must have been diagnosed with gastroparesis, vision loss, and bowel obstruction after taking GLP-1 RA medications

We encourage you to reach out to Atraxia Law for a case evaluation. If you meet the eligibility criteria we will refer you to an attorney who will file the claim on your behalf.